New treatment paradigms for ADPKD: moving towards precision medicine (Q49494721)

20 February 2018

title

New treatment paradigms for ADPKD: moving towards precision medicine (English)

1 reference

20 February 2018

1 reference

20 February 2018

author name string

Arlene B Chapman

series ordinal

1 reference

20 February 2018

language of work or name

English

0 references

publication date

9 October 2017

1 reference

20 February 2018

Nature Reviews Nephrology

published in

1 reference

20 February 2018

volume

1 reference

20 February 2018

issue

1 reference

20 February 2018

page(s)

750-768

1 reference

20 February 2018

ESRD from autosomal dominant polycystic kidney disease in the United States, 2001-2010.

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival--an analysis of data from the ERA-EDTA Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Incidence and survival of end-stage kidney disease due to polycystic kidney disease in Australia and New Zealand (1963-2014).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Blood pressure in early autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Genetics and pathogenesis of autosomal dominant polycystic kidney disease: 20 years on.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Isolated polycystic liver disease genes define effectors of polycystin-1 function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Vasopressin directly regulates cyst growth in polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Renal injury is a third hit promoting rapid development of adult polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Scattered Deletion of PKD1 in Kidneys Causes a Cystic Snowball Effect and Recapitulates Polycystic Kidney Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Phenomics: the next challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Phenomics: expanding the role of clinical evaluation in genomic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Determinants of renal volume in autosomal-dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Rationale for early treatment of polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

The PROPKD Score: A New Algorithm to Predict Renal Survival in Autosomal Dominant Polycystic Kidney Disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Predictors of autosomal dominant polycystic kidney disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Refining Genotype-Phenotype Correlation in Autosomal Dominant Polycystic Kidney Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Type of PKD1 mutation influences renal outcome in ADPKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Polycystic Kidney Disease without an Apparent Family History

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Family history of renal disease severity predicts the mutated gene in ADPKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Mutations in GANAB, Encoding the Glucosidase IIα Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Technical Evaluation: Identification of Pathogenic Mutations in PKD1 and PKD2 in Patients with Autosomal Dominant Polycystic Kidney Disease by Next-Generation Sequencing and Use of a Comprehensive New Classification System.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Whole-genome sequencing overcomes pseudogene homology to diagnose autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Mutations in multiple PKD genes may explain early and severe polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

LRP5 variants may contribute to ADPKD

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Assessing Risk of Disease Progression and Pharmacological Management of Autosomal Dominant Polycystic Kidney Disease: A Canadian Expert Consensus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Unified criteria for ultrasonographic diagnosis of ADPKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Total Kidney Volume as a Biomarker of Disease Progression in Autosomal Dominant Polycystic Kidney Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Comparison of Total Kidney Volume Quantification Methods in Autosomal Dominant Polycystic Disease for a Comprehensive Disease Assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

The importance of total kidney volume in evaluating progression of polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Sirolimus and kidney growth in autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Everolimus in patients with autosomal dominant polycystic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Angiotensin blockade in late autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Low-dose rapamycin (sirolimus) effects in autosomal dominant polycystic kidney disease: an open-label randomized controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Sirolimus therapy to halt the progression of ADPKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Automated Segmentation of Kidneys from MR Images in Patients with Autosomal Dominant Polycystic Kidney Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Estimation of total kidney volume in autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Total Kidney Volume Is a Prognostic Biomarker of Renal Function Decline and Progression to End-Stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Urine and plasma osmolality in patients with autosomal dominant polycystic kidney disease: reliable indicators of vasopressin activity and disease prognosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

A case for water in the treatment of polycystic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Kidney function and plasma copeptin levels in healthy kidney donors and autosomal dominant polycystic kidney disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Copeptin levels and kidney function in ADPKD: case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Copeptin, a Surrogate Marker of Vasopressin, Is Associated with Disease Severity in Autosomal Dominant Polycystic Kidney Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Association of arginine vasopressin surrogate marker urinary copeptin with severity of autosomal dominant polycystic kidney disease (ADPKD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Proteomics of Urinary Vesicles Links Plakins and Complement to Polycystic Kidney Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Urine Exosome Isolation and Characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Identification of Biomarkers for PKD1 Using Urinary Exosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Urinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Hypertension in autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Synaptopodin Limits TRPC6 Podocyte Surface Expression and Attenuates Proteinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Cardiovascular complications in autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

[Ca2+]i reduction increases cellular proliferation and apoptosis in vascular smooth muscle cells: relevance to the ADPKD phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Mechanisms and management of hypertension in autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Pheochromocytoma as a rare cause of arterial hypertension in a patient with autosomal dominant polycystic kidney disease: A diagnostic and therapeutic dilemma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

A case of primary aldosteronism revealed after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

ACE inhibitors, left ventricular mass and renal cyst growth in ADPKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

No effect of enalapril on progression in autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Diuretics versus angiotensin-converting enzyme inhibitors in autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Intensive Blood-Pressure Control in Hypertensive Chronic Kidney Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Association between strict blood pressure control during chronic kidney disease and lower mortality after onset of end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

A Randomized Trial of Intensive versus Standard Blood-Pressure Control

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Precision Medicine for Hypertension Management in Chronic Kidney Disease: Relevance of SPRINT for Therapeutic Targets in Nondiabetic Renal Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Co-existing autosomal dominant polycystic kidney disease and nephrotic syndrome in a Nigerian patient with lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Analysis of baseline parameters in the HALT polycystic kidney disease trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Renal hemodynamic effects of the HMG-CoA reductase inhibitors in autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Effect of pravastatin on kidney function and urinary protein excretion in autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Treatments to slow progression of autosomal dominant polycystic kidney disease: systematic review and meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Somatostatin analog therapy for severe polycystic liver disease: results after 2 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Hepatic Cyst Infection During Use of the Somatostatin Analog Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open-Label Multicenter DIPAK-1 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

microRNA-17 family promotes polycystic kidney disease progression through modulation of mitochondrial metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Therapeutic microRNAs in polycystic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Medical resource utilization and costs associated with autosomal dominant polycystic kidney disease in the USA: a retrospective matched cohort analysis of private insurer data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Diagnostic Algorithm in the Management of Acute Febrile Abdomen in Patients with Autosomal Dominant Polycystic Kidney Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Evaluation and management of pain in autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Clinical features of cyst infection and hemorrhage in ADPKD: new diagnostic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

International Multi-Specialty Delphi Survey: Identification of Diagnostic Criteria for Hepatic and Renal Cyst Infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Diagnostic criteria in renal and hepatic cyst infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

18F-FDG PET/CT during diagnosis and follow-up of recurrent hepatic cyst infection in autosomal dominant polycystic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Intracystic magnetic resonance imaging in patients with autosomal dominant polycystic kidney disease: features of severe cyst infection in a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Positron emission tomography in the diagnostic pathway for intracystic infection in adpkd and "cystic" kidneys. a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Cyst infection in autosomal dominant polycystic kidney disease: causative microorganisms and susceptibility to lipid-soluble antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Evaluation of nephrolithiasis in autosomal dominant polycystic kidney disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Renal stone disease in autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Percutaneous nephrolithotomy for large or multiple upper tract calculi and autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Management of Renal Stone Disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Factors associated with patient recall of individualized dietary recommendations for kidney stone prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Medical management to prevent recurrent nephrolithiasis in adults: a systematic review for an American College of Physicians Clinical Guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Novel treatment protocol for ameliorating refractory, chronic pain in patients with autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

A stepwise approach for effective management of chronic pain in autosomal-dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Management of pain in autosomal dominant polycystic kidney disease and anatomy of renal innervation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Management of chronic pain in a patient with autosomal dominant polycystic kidney disease by sequential celiac plexus blockade, radiofrequency ablation, and spinal cord stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

A review of the thoracic splanchnic nerves and celiac ganglia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Chronic kidney pain in autosomal dominant polycystic kidney disease: a case report of successful treatment by catheter-based renal denervation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

A controlled trial of renal denervation for resistant hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Long-term impact of laparoscopic cyst decortication on renal function, hypertension and pain control in patients with autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Surgical cyst decortication in autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Spot urine sodium measurements do not accurately estimate dietary sodium intake in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

The association between dietary sodium intake, ESRD, and all-cause mortality in patients with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Dietary Sodium and Cardiovascular Disease Risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Compared with usual sodium intake, low- and excessive-sodium diets are associated with increased mortality: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Sodium intake, ACE inhibition, and progression to ESRD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Dietary protein intake and chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

North American experience with Low protein diet for Non-dialysis-dependent chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

A dietary quality comparison of popular weight-loss plans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Effect of dietary protein restriction on the progression of kidney disease: long-term follow-up of the Modification of Diet in Renal Disease (MDRD) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

The medicinal use of water in renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

A pilot clinical study to evaluate changes in urine osmolality and urine cAMP in response to acute and chronic water loading in autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Water prescription in autosomal dominant polycystic kidney disease: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Does increased water intake prevent disease progression in autosomal dominant polycystic kidney disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Apelin and copeptin: two opposite biomarkers associated with kidney function decline and cyst growth in autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Serum uric acid, kidney volume and progression in autosomal-dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Soluble klotho and autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Association of Urinary Biomarkers With Disease Severity in Patients With Autosomal Dominant Polycystic Kidney Disease: A Cross-sectional Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Evaluation of urine biomarkers of kidney injury in polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Urinary EGF Receptor Ligand Excretion in Patients with Autosomal Dominant Polycystic Kidney Disease and Response to Tolvaptan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

One hundred ABO-incompatible kidney transplantations between 2004 and 2014: a single-centre experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Effect of Sirolimus on Disease Progression in Patients with Autosomal Dominant Polycystic Kidney Disease and CKD Stages 3b-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

WHO analgesic ladder: a good concept gone astray

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Lowering of Pkd1 expression is sufficient to cause polycystic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Neonatal onset autosomal dominant polycystic kidney disease (ADPKD) in a patient homozygous for aPKD2missense mutation due to uniparental disomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Volume progression in polycystic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Hypertension and Autosomal Dominant Polycystic Kidney Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Improvement of endothelial dysfunction with simvastatin in patients with autosomal dominant polycystic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Effect of Statin Therapy on the Progression of Autosomal Dominant Polycystic Kidney Disease. A Secondary Analysis of the HALT PKD Trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Reversible renal failure associated with angiotensin-converting enzyme inhibitors in polycystic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Anatomic and metabolic risk factors for nephrolithiasis in patients with autosomal dominant polycystic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Laparoscopic renal denervation for intractable ADPKD-related pain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Thoracoscopic renal denervation for intractable autosomal dominant polycystic kidney disease-related pain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Altered dietary salt intake for people with chronic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Sodium and cardiovascular disease - Authors' reply

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Commentary: Accepting what we don't know will lead to progress

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

A method for estimating nitrogen intake of patients with chronic renal failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Low protein diets for chronic kidney disease in non diabetic adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Evaluation of Fibrosis Markers: Apelin and Transforming Growth Factor-β1 in Autosomal Dominant Polycystic Kidney Disease Patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Serum uric acid levels and endothelial dysfunction in patients with autosomal dominant polycystic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Fibroblast growth factor 23 and soluble Klotho in patients with autosomal dominant polycystic kidney disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2017.127

Management of renal cyst infection in patients with autosomal dominant polycystic kidney disease: a systematic review

31 March 2020

1 reference

12 December 2020

Urine peptidome analysis predicts risk of end-stage renal disease and reveals proteolytic pathways involved in autosomal dominant polycystic kidney disease progression.

1 reference

12 December 2020

Dissidents and dietary sodium: concerns about the commentary by O'Donnell et al

1 reference

12 December 2020

Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. Modification of Diet in Renal Disease Study Group

1 reference

12 December 2020

Hypertension in autosomal dominant polycystic kidney disease

1 reference

12 December 2020

Coexistence of autosomal dominant polycystic kidney disease and amyloidosis in a patient with nephrotic-range proteinuria

1 reference

12 December 2020

Identification of patients with autosomal dominant polycystic kidney disease at highest risk for end-stage renal disease

1 reference

12 December 2020

Left ventricular hypertrophy in autosomal dominant polycystic kidney disease

1 reference

12 December 2020

Molecular diagnosis of autosomal dominant polycystic kidney disease

1 reference

12 December 2020

Secreted frizzled-related protein 4 predicts progression of autosomal dominant polycystic kidney disease.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRNEPH.2017.127

1 reference

20 February 2018

1 reference

20 February 2018